Infection . Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a

[tetano]

Infection


. 2021 Jul 9.
doi: 10.1007/s15010-021-01657-y. Online ahead of print.
Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany


Johanna Koehler[SUP] 1 [/SUP], Barbara Ritzer[SUP] 1 [/SUP], Simon Weidlich[SUP] 1 [/SUP], Friedemann Gebhardt[SUP] 2 [/SUP], Chlodwig Kirchhoff[SUP] 3 [/SUP], Jens Gempt[SUP] 4 [/SUP], Christiane Querbach[SUP] 5 [/SUP], Dieter Hoffmann[SUP] 6 [/SUP], Bernhard Haller[SUP] 7 [/SUP], Roland M Schmid[SUP] 1 [/SUP], Jochen Schneider[SUP] 1 [/SUP], Christoph D Spinner[SUP] 1 [/SUP], Roman Iakoubov[SUP] 8 [/SUP]



Affiliations

• PMID: 34244967
• DOI: 10.1007/s15010-021-01657-y

Abstract

Additional treatment options for coronavirus disease (COVID-19) are urgently needed, particularly for populations at high risk of severe disease. This cross-sectional, retrospective study characterized the outcomes of 43 patients with nosocomial severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection with and without treatment using monoclonal SARS-CoV-2 spike antibodies (bamlanivimab or casirivimab/imdevimab). Our results indicate that treatment with monoclonal antibodies results in a significant decrease in disease progression and mortality when used for asymptomatic patients with early SARS-CoV-2 infection.

Keywords: Bamlanivimab; COVID-19; Casirivimab; Imdevimab; Monoclonal spike antibodies; SARS-CoV2.